$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Ovarian cancer is the eighth most common malignancy in women worldwide, with approximately 300,000 new diagnoses and an estimated 180,000 deaths annually1. At initial diagnosis, ovarian cancer often presents with severe symptoms, with about 75% of patients already at stage III-IV. Accordingly, the 5-year survival rate is <30% and the mortality rate is the highest among gynecological cancers2, with the efficiency of treatment for ovarian cancer being highly dependent on clinical factors such as the successful accomplishment of debulking surgery, resistance to chemotherapy, and recurrence after the initial therapy.
Ovarian cancer tissues are hierarchically organized, with not all tumor components being equally capable of generating descendants. The only cells able to self-renew and produce a heterogeneous tumor cell population are considered to represent cancer stem cells (CSCs)3. CSC self-renewal and tumor initiation are accompanied by the promotion of angiogenesis to remodel their tumor microenvironment for the purpose of maintaining a supportive niche. However, previous models could not be utilized for in vitro analyses because of the limited reproducibility of cultivating CSCs derived from clinical samples owing to the disruption of spheroids after multiple passaging. More recently, experimental methods to cultivate CSCs from patients have been developed for several applications4,5,6,7. In particular, by exploiting the characteristic of CSCs to grow by forming spheroids in ultra-low attachment plates with serum-free medium, the cultivated CSCs are induced to express a stem-cell surface marker that is not expressed in normal tumor cells with multilineage differentiation potential8,9.
Recent data have shown that the persistence of dormant ovarian (O)CSCs visualized as dissemination at the peritoneum is associated with their regeneration as recurrent tumors10. Understanding the molecular and biological features of OCSCs may thus allow for effective targeting and eradication of these cells, resulting in potential tumor remission. In particular, little is known regarding the cellular and molecular mechanistic features of CSCs roles in angiogenesis11. Therefore, in the present protocol we used patient-derived OCSCs in an in vitro setting to investigate the angiogenic property of endothelial cells using the co-culture model, which may mimic the tumor microenvironment of CSCs and endothelial cells at the metastatic site in the clinical setting. Ultimately, as neovascularization constitutes a critical process necessary to support tumor growth and metastasis, a better understanding of its mechanism will allow the development of a novel targeting therapy for OCSCs at the metastatic site.
Here, we present a protocol to visualize the neovascularization step surrounding the CSCs in a time course manner. The advantage of the protocol includes allowing fully reproducible investigations using the 3D co-culture system, NICO-1, thereby permitting observation of the effects on patients of the OCSC-derived tumor-initiation capability during endothelial cell angiogenesis.